.jpeg)
Has the targeted drug Trametinib been launched in China?
In December 2019, the National Medical Products Administration approved trametinib and dabrafenib, two original targeted combination therapies, to be launched in China for the treatment of BRAF V600For patients with mutation-positive unresectable or metastatic melanoma and non-small cell lung cancer, due to its short time on the market, V600 may be limited to patients who meet the indications for trametinib after entering the medical insurance ranks. The reimbursement ratio varies in different regions, and the price after reimbursement is different. Specifications2mg*30Price per box The price is around 2 around , and the price of 0.5mg*30 tablets is around 1 around , which is expensive.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
